Exact Sciences to acquire Thrive Earlier Detection in deal worth up to $2.15 billionChristian Fernsby ▼ | October 27, 2020
Exact Sciences said Tuesday it has agreed to acquire Thrive Earlier Detection in a cash and stock deal worth up to $2.15 billion.
Thrive Earlier Detection Exact Sciences
Topics: Exact Sciences Thrive Earlier Detection
The deal is expected to close in the first quarter of 2021.
"Combining Thrive's pioneering early stage screening test, CancerSEEK, with Exact Sciences' best in class scientific platform, clinical organization, and commercial infrastructure will establish Exact Sciences as a leading competitor in blood based, multi cancer screening," the company said in a statement. ■